Pharmacogenetics Newsletter

Volume 3, Issue 27, 07/19/2011

Question

Why are patients with genetic polymorphisms to CYP2D6 more likely to have weight loss and tachycardia while taking atomoxetine (Strattera)?

Answer

Atomoxetine (Strattera) is a non-stimulant medication that is most commonly used in the treat attention-deficit/hyperactivity disorder (ADHD).¹  Instead of increasing the release of norepinephrine in the central nervous system, it works to selectively inhibit the reuptake of norepinephrine.¹   The degree of increase in norepinephrine can directly influence the risk for side effects or adverse drug events.